[HTML][HTML] The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis

SA Klassen, JW Senefeld, PW Johnson, RE Carter… - Mayo Clinic …, 2021 - Elsevier
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated
patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose …

Hematological manifestations of SARS‐CoV‐2 in children

C Kosmeri, E Koumpis, S Tsabouri… - Pediatric blood & …, 2020 - Wiley Online Library
Infection from severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), though
mainly a respiratory disease, can impair many systems, including causing hematological …

Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C

H Whitworth, SE Sartain, R Kumar… - Blood, The Journal …, 2021 - ashpublications.org
Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) is associated with thrombotic complications in …

Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19

LA Vella, JR Giles, AE Baxter, DA Oldridge… - Science …, 2021 - science.org
Pediatric coronavirus disease 2019 (COVID-19) after SARS-CoV-2 infection is associated
with fewer hospitalizations and often milder disease than in adults. A subset of children …

Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction

C Diorio, R Shraim, LA Vella, JR Giles… - Nature …, 2021 - nature.com
Abstract Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in pediatric …

Convalescent plasma may be a possible treatment for COVID-19: A systematic review

Y Wang, P Huo, R Dai, X Lv, S Yuan, Y Zhang… - International …, 2021 - Elsevier
Introduction The coronavirus disease 2019 (COVID-19) pandemic has spread globally.
Therapeutic options including antivirals, anti-inflammatory compounds, and vaccines are still …

COVID 19 infection: pediatric perspectives

A Adeyinka, K Bailey, L Pierre… - Journal of the American …, 2021 - Wiley Online Library
Abstract The coronavirus disease 2019 (COVID‐19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has rapidly spread across the globe …

How should we use convalescent plasma therapies for the management of COVID-19?

EM Wood, LJ Estcourt… - Blood, The Journal of the …, 2021 - ashpublications.org
Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory
syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate …

COVID-19 in children: clinical manifestations and pharmacologic interventions including vaccine trials

R Galindo, H Chow, C Rongkavilit - Pediatric Clinics, 2021 - pediatric.theclinics.com
There have been reports of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
infecting children in all age groups; however, children still comprise a small percentage of …

[HTML][HTML] Convalescent plasma for the prevention and treatment of COVID-19: a systematic review and quantitative analysis

HT Peng, SG Rhind, A Beckett - JMIR Public Health and …, 2021 - publichealth.jmir.org
Background: The COVID-19 pandemic, caused by a novel coronavirus termed SARS-CoV-2,
has spread quickly worldwide. Convalescent plasma (CP) obtained from patients following …